BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Multiple Therapy Groups record double-digit value growth in IPM October 2026

14 November 2026 | News | By Narayan Kulkarni

Anti-neoplastics recorded the highest value growth among the major therapy categories



Several therapy segments in India's pharmaceutical market (IPM) recorded double-digit value growth in October 2026, led by anti-neoplastic medicines, vitamins and minerals, blood-related therapies and vaccines, according to data from Pharmarack Technologies.

Anti-neoplastics recorded the highest value growth among the major therapy categories, expanding 18.7 per cent during October 2026. Vitamins, minerals and nutrients followed with 17 per cent growth, while blood-related therapies registered 16.3 per cent growth.

Vaccines recorded 15.3 per cent value growth, while anti-diabetic medicines expanded 14.7 per cent. Gastrointestinal therapies registered 14.2 per cent growth, followed by cardiac medicines at 13.5 per cent.

Other segments recording double-digit value growth included gynaecological therapies at 15.9 per cent, pain and analgesics at 14.9 per cent, dermatology at 12.7 per cent, and neuro and central nervous system (CNS) therapies at 10.9 per cent.

Urology registered 10.5 per cent growth, while stomatologicals and sex stimulants/rejuvenators recorded 10.4 per cent and 7.2 per cent, respectively. The latter two did not both cross the double-digit threshold, with sex stimulants/rejuvenators remaining below it.

The performance of these therapy groups comes against an overall Indian Pharmaceutical Market (IPM) value growth of 12.23 per cent in October, with monthly sales reaching Rs 24,212 crore.

In terms of market contribution, cardiac medicines remained the largest therapy segment, accounting for 13.8 per cent of the market, followed by anti-infectives at 11.6 per cent and gastrointestinal medicines at 11.5 per cent. Anti-diabetic medicines contributed 9.6 per cent, while vitamins, minerals and nutrients accounted for 9.2 per cent.

Notably, anti-infectives, which contributed 11.6 per cent to the market, recorded only 6.9 per cent value growth during the month. Respiratory medicines grew 3.8 per cent, while hormones registered 7.2 per cent.

Sharing insights on the market, Sheetal Sapale, Vice President – Commercial, Pharmarack Technologies, highlighted the October performance, which reflected broad-based value expansion across several therapy segments.

The data point to continued growth momentum in specialised and chronic therapy categories, including oncology, diabetes and cardiovascular care, alongside vaccines and nutritional products.

Narayan Kulkarni

(narayan.kulkarni@mmactiv.com)